Charles Bidgood
YOU?
Author Swipe
View article: Spatial Multiomic Profiling Identifies Metabolic and Inflammatory Signatures Driving Recurrence in Adjuvant-Treated NSCLC
Spatial Multiomic Profiling Identifies Metabolic and Inflammatory Signatures Driving Recurrence in Adjuvant-Treated NSCLC Open
While there have been therapeutic advancements in treatments for non-small cell lung cancer (NSCLC), we have a limited understanding of how the tumour composition and spatial heterogeneity influences clinical outcomes. Here, we performed a…
View article: Pre-pregnancy obesity is associated with an altered maternal metabolome and reduced Flt3L expression in preterm birth
Pre-pregnancy obesity is associated with an altered maternal metabolome and reduced Flt3L expression in preterm birth Open
View article: Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancer
Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancer Open
View article: Valine Catabolism Drives Bioenergetic and Lipogenic Fuel Plasticity in Prostate Cancer
Valine Catabolism Drives Bioenergetic and Lipogenic Fuel Plasticity in Prostate Cancer Open
Metabolic reprogramming is a hallmark of cancer and fundamental for disease progression. The remodelling of oxidative phosphorylation and enhanced lipogenesis are key characteristics of prostate cancer (PCa). Recently, succinate-dependent …
View article: Metabolomics at the tumor microenvironment interface: Decoding cellular conversations
Metabolomics at the tumor microenvironment interface: Decoding cellular conversations Open
Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered energetics is one of the hallmarks of cancer and influences tumor growth and drug resistance. Studies have shown that heterogeneity exists within…
View article: Investigating the role of mitochondrial energy rewiring throughout prostate cancer progression
Investigating the role of mitochondrial energy rewiring throughout prostate cancer progression Open
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men. Despite effective first-line therapies, approximately 30% of patients will recur with advanced disease, highlighting an unmet clinical burden. This project investi…
View article: Leptin antagonism inhibits prostate cancer xenograft growth and progression
Leptin antagonism inhibits prostate cancer xenograft growth and progression Open
Hyperleptinaemia is a well-established therapeutic side effect of drugs inhibiting the androgen axis in prostate cancer (PCa), including main stay androgen deprivation therapy (ADT) and androgen targeted therapies (ATT). Given significant …
View article: Apocryphal FADS2 activity promotes fatty acid diversification in cancer
Apocryphal FADS2 activity promotes fatty acid diversification in cancer Open
View article: Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging
Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging Open
The spirooxepinisoxazoline alkaloid psammaplysin F (1) was selected as a scaffold for the generation of a unique screening library for both drug discovery and chemical biology research. Large-scale extraction and isolation chemistry…
View article: Metabolic plasticity in cancer activates apocryphal pathways for lipid desaturation
Metabolic plasticity in cancer activates apocryphal pathways for lipid desaturation Open
Fatty acid (FA) modifications, such as enzymatic desaturation and elongation, have long been thought to involve sequential and highly specific enzyme-substrate interactions, which result in canonical products that are well-defined in their…
View article: Isomer-resolved lipidomics for analysis of human prostate tumours and cancer cell lines
Isomer-resolved lipidomics for analysis of human prostate tumours and cancer cell lines Open
View article: Adaptive prostate cancer cell metabolism following combined anti-androgen and biguanide treatment
Adaptive prostate cancer cell metabolism following combined anti-androgen and biguanide treatment Open
Emerging treatments for advanced prostate cancer continue to target androgen signalling leading to prolonged androgen deprivation. This induces metabolic dysfunction and hyperinsulinaemia which is specifically associated with more rapid tr…